DAAs
ApprovedSmall molecule
DAAs is one of 64 small molecule programs targeting Hepatic fibrosis. It is currently in Approved.
3
Indications
5
Total Trials
0
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
624 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1DAAs
TThird Affiliated Hospital, Sun Yat-Sen University
Approved
PEG-Intron
Merck & Co.Preclinical
Sovaldi
GileadPreclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Incivek
Vertex PharmaceuticalsPreclinical
Intron a
SanofiPreclinical
Roferon-a
RochePreclinical
Medrol
PfizerPreclinical
Dasabuvir
AbbViePreclinical
SOF/VEL
GileadPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis2 trials
Antiviral Drug1 trial
Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital
Unknown status·—··NCT03965286·80 enrolled
Hepatic fibrosis1 trial
Clinical Impacts of Achieving SVR in Patients With Advanced Hepatic Fibrosis Related to Chronic HCV Treated With Direct Acting Antivirals
Completed·—··NCT03884062·3,000 enrolled
Hepatitis C1 trial
Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages
Completed·—·Phase 4·NCT04177043·221,855 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DAAs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details